Business Description
Zura Bio Limited is a clinical-stage company focused on developing treatments for autoimmune and inflammatory diseases. Its lead drug candidate, Tibulizumab, is currently in Phase 2 trials and works by blocking two key proteins involved in these conditions within a single molecule. The company also has two other drug candidates, Torudokimab and Crebankitug, each targeting different proteins linked to inflammation, both of which have completed early-stage clinical testing. Founded in 2022 and based in Henderson, Nevada, Zura Bio is building a focused portfolio aimed at addressing serious immune-related conditions.
